sasutezew.blogspot.com
The Department of Health’s proposed regulationws related to marketing activities by pharmaceuticalk and medical device manufacturersz will create an unquestionably restrictive environmen t forthese companies. However, the administrationj wisely opted to exclude from the requirements disclosure of legitimate payments related toclinicao trials. A vocal minority has sincw raiseda stink, suggesting that the state health officials caved to This is ridiculous. The administration has simpl done theright thing.
Recengt data from showed that in 2005, biopharmaceutical-related companies were responsiblre foralmost 55,000 jobs in the The university’s also projected that 15,000 new jobs in the biopharmaceuticak industry will be generated in Massachusette by 2014. Lawmakers showerd great determination and vision in championinb the recently enacted life sciences These efforts could have been jeopardizeds if not for the actions of the Department of Health.
Our state officials took crucial stepse to ensure that ongoing clinical research conducted in partnership betweeh local physicians and academic medical centers and life sciencezs companies is not threatened by overly restrictivedisclosure requirements. It is the right decisiohn for thepublic health, for this uniquer and dynamic life sciences and for the near-term prospects of our localk economy.
Kelly Thompson Clark Presidentand CEO,
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment